Peptide-based vectors for blood-brain barrier targeting and delivery of drugs to the central nervous system

Therapeutic Delivery

Volumn 1, Issue 4, 2010, Pages 489-494

  Vlieghe, Patrick ^a   Khrestchatisky, Michel ^b  

^a CS80011   (France)

^b Mediterranée University   (France)

Author keywords

adsorptive mediated transport; biotechnology companies; carrier mediated transport; drug conjugate; liposomes; nanoparticles; prodrug; receptor mediated transcytosis; transcellular diffusion

Indexed keywords

ABC TRANSPORTER; AGT 181; ANG 1005; ANGIOPEP 2; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; DOXORUBICIN; DRUG CARRIER; GLUTATHIONE; GLYCOPROTEIN P; HYBRID PROTEIN; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN 4; NANOCARRIER; OPIATE PEPTIDE; PACLITAXEL; POLY(BUTYLCYANOACRYLATE); PRODRUG; PROTEIN P57; RIBAVIRIN; UNCLASSIFIED DRUG; VH 0411; VH 0445;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUSTRY; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; GLIOBLASTOMA; HUMAN; HURLER SYNDROME; LIGAND BINDING; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; NANOENCAPSULATION; NERVE CELL MEMBRANE; NEUROPROTECTION; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS;

EID: 79954484426     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.44     Document Type: Review

References (59)

1. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 6(1), 79-87 (2005).
2. El-Bacha RS, Minn A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol. Biol. 45(1), 15-23 (1999).
3. Wekerle, H. Immune protection of the brain - efficient and delicate. J. Infect. Dis. 186 (Suppl. 2), S140-144 (2002). (Pubitemid 35370473)
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3(8), 711-715 (2004). (Pubitemid 39173511)
5. Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6(7), 521-532 (2007). (Pubitemid 47019441)
6. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 3(2), 90-105 (2003).
7. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1), 3-14 (2005). (Pubitemid 40128022)
8. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurbiol. Dis. 37(1), 48-57 (2010).
9. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 24(9), 1745-1758 (2007). (Pubitemid 47206624)
10. Mazza M, Uchegbu IF, Schtzlein AG. Cancer and the blood-brain barrier: Trojan horses for courses? Br. J. Pharmacol. 155(2), 149-151 (2008).
11. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Therapeut. 104(1), 29-45 (2004). (Pubitemid 39410561)
12. De Boer AG, Gaillard PJ. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 47, 323-355 (2007).
13. Zhang Y, Han H, Elmquist WF, Miller DW. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 876(1-2), 148-153 (2000).
14. Pardridge WM. Blood-brain barrier delivery. Drug Discov. Today 12(1-2), 54-61 (2007). (Pubitemid 46014479)
15. Broadwell RD, Balin BJ, Selcman M. Transcytotic pathways for blood-borne protein through the blood-brain barrier. Proc. Natl Acad. Sci. USA 85(2), 632-636 (1988). (Pubitemid 18059323)
16. Palmer AM. The role of the blood-CNS barrier in CNS disorders and their treatment. Neurbiol. Dis. 37(1), 3-12 (2010).
17. Kreuter J, Shamenkov D, Petrov V et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood- brain barrier. J. Drug Target. 10(4), 317-325 (2002). (Pubitemid 34746313)
18. Kreuter J, Ramge P, Petrov V et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20(3), 409-416 (2003). (Pubitemid 36288370)
19. Demeule M, Régina A, Ché C et al. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324(3), 1064-1072 (2008). (Pubitemid 351397849)
20. Demeule M, Currie JC, Bertrand Y et al. Involvement of the low-density lipoprotein receptor related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106(4), 1534-1544 (2008).
21. Régina A, Demeule M, Ché C et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155(2), 185-197 (2008).
22. Demeule M, Poirier J, Jodoin J et al. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem. 83(4), 924-933 (2002). (Pubitemid 35316043)
23. Brown MS, Goldstein JL. Receptor-mediated endocytosis: insights from the lipoprotein receptor system. Proc. Natl Acad. Sci. 76(7), 3330-3337 (1979). (Pubitemid 9233955)
24. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138(4), 877-889 (1997). (Pubitemid 27365049)
25. Chung NS, Wasan KM. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv. Drug Deliv. Rev. 56(9), 1315-1334 (2004). (Pubitemid 38510476)
26. Reichel, A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Chem. Biodivers. 6(11), 2030-2049 (2009).
27. Hammarlund-Udenaes M, Fridén M, Syvnen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm. Res. 25(8), 1737-1750 (2008).
28. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov. Today 15(1-2), 40-56 (2010).
29. Mehdipour AR, Hamidi M. Brain drug targeting: a computational approach for overcoming blood-brain barrier. Drug Discov. Today 14(21-22), 1030-1036 (2009).
30. Industrial Technology Research Institute: US0141133 (2007).
31. To-BBB, Holding BV: WO08118013 (2008).
32. Industrial Technology Research Institute: US0095836 (2008).
33. Industrial Technology Research Institute: US0123531 (2009).
34. NanoDel Technologies, Gmbh: WO04017945 (2004).
35. NanoDel Technologies, Gmbh: WO06029845 (2006).
36. NanoDel Technologies, Gmbh: WO06056362 (2006).
37. NanoDel Technologies, Gmbh: WO07088066 (2007).
38. NanoDel Technologies, Gmbh: WO08003706 (2008).
39. AngioChem, Inc.: WO04060403 (2004).
40. AngioChem, Inc.: WO06086870 (2006).
41. AngioChem, Inc.: WO07009229 (2007).
42. AngioChem, Inc.: WO08046228 (2008).
43. AngioChem, Inc.: WO09079790 (2009).
44. AngioChem, Inc.: WO09127072 (2009).
45. AngioChem, Inc.: WO10043047 (2010).
46. AngioChem, Inc.: WO10043049 (2010).
47. AngioChem, Inc.: WO10063122 (2010).
48. AngioChem, Inc.: WO10063123 (2010).
49. AngioChem, Inc.: WO10063124 (2010).
50. ArmaGen Technologies, Inc.: WO07044323 (2007).
51. ArmaGen Technologies, Inc.: WO08022349 (2008).
52. ArmaGen Technologies, Inc.: WO09018122 (2009).
53. ArmaGen Technologies, Inc.: WO09070597 (2010).
54. Raptor Pharmaceutical, Inc.: WO06138343 (2006).
55. Raptor Pharmaceutical, Inc.: WO07035716 (2007).
56. Raptor Pharmaceutical, Inc.: WO08036682 (2008).
57. Raptor Pharmaceutical, Inc.: WO08116171 (2008).
58. Vect-Horus, SAS: FR2937322 (2010).
59. Vect-Horus, SAS: WO10046588 (2010).